A phase II antiemetic combination (COMD) for cisplatin-induced nausea and vomiting.
Thirteen patients resistant to high-dose metoclopramide (greater than or equal to 5 emetic episodes in 24 h following chemotherapy) were treated in the subsequent course of CDDP chemotherapy with COMD (chlorpromazine, orphenadrine, metoclopramide, dexamethasone). A statistically significant reduction in the number of vomiting episodes was obtained, and 69% of patients showed a better acceptance of CDDP treatment. Subsequently, the same antiemetic combination was administered to 31 untreated patients receiving CDDP alone for the first time: 67.7% obtained complete protection from vomiting with minimal toxicity. According to our experience, COMD is an efficacious and well-tolerated antiemetic combination in cisplatin-treated patients; however, further studies with larger numbers of patients are required to confirm these preliminary results.
D000328:Adult; D000368:Aged; D000932:Antiemetics / Q000627:therapeutic use*; D002746:Chlorpromazine / Q000627:therapeutic use*; D003907:Dexamethasone / Q000627:therapeutic use*; D004338:Drug Combinations / Q000627:therapeutic use; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008787:Metoclopramide / Q000627:therapeutic use*; D008875:Middle Aged; D009966:Orphenadrine / Q000627:therapeutic use*
D000932:Antiemetics; D004338:Drug Combinations; C050340:chlorpromazine, dexamethasone, metoclopramide, orphenadrine drug combination; D003907:Dexamethasone; D009966:Orphenadrine; D008787:Metoclopramide; D002746:Chlorpromazine